Skip to main content

Table 5 Clinical events in the cohort of NVAF patients treated with Apixaban and warfarin

From: Estimation of the cost-effectiveness of apixaban versus vitamin K antagonists in the management of atrial fibrillation in Argentina

   VKA Suitable patients
Number of events (Total population)ischemic strock Apixaban Warfarin
Non-fatal Mild 80 80
Non-fatal Moderate 68 73
Non-fatal Severe 27 28
Fatal 25 25
TOTAL 200 206
Recurrent Islamic Stroke   
Non-fatal Mild 4 4
Non-fatal Moderate 6 7
Non-fatal Severe 5 6
Fatal 4 4
TOTAL 20 21
Hemorrhagic Stroke   
Non-fatal Mild 4 7
Non-fatal Moderate 6 6
Non-fatal Severe 4 6
Fatal 9 21
TOTAL 23 40
Recurrent Hemorrhagic Stroke   
Non-fatal Mild 0 0
Non-fatal Moderate 0 0
Non-fatal Severe 0 1
Fatal 0 0
TOTAL 1 2
Systematic Embolism   
Non fatal 19 19
Fatal 2 2
TOTAL 22 21
Other ICH   
Non fatal 9 21
Fatal 1 3
TOTAL 11 24
Other Major Bleeds   
Non-fatal GI Bleeds 54 55
Non-fatal Non ICH or Non GI Related Major Bleeds Fatal 88 98
Fatal 3 3
TOTAL 145 155
Clinically Relevant Non-Major Bleeds 252 287
MI   
Non fatal 67 67
Fatal 8 8
TOTAL 75 75
Other CV Hospitalization 1.060 1.020
Other Treatment Discontinuation 579 591
Deaths   
Event Related (acute) 51 65
Event related (death due to stroke, HS,MI, SE) 273 285
Other 676 650
TOTAL 1.000 1.000